Shares of NewLink Genetics Corp. (NASDAQ:NLNK) were down 1.1% during mid-day trading on Friday . The stock traded as low as $10.07 and last traded at $10.20, with a volume of 150,225 shares changing hands. The stock had previously closed at $10.31.

Several analysts have issued reports on NLNK shares. Mizuho cut their price target on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Robert W. Baird reissued an “outperform” rating and set a $23.00 price target (down previously from $27.00) on shares of NewLink Genetics Corp. in a report on Tuesday, May 10th. SunTrust Banks Inc. downgraded NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $59.00 to $12.00 in a research report on Tuesday, May 10th. Zacks Investment Research downgraded NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, Jefferies Group restated a “hold” rating and issued a $10.00 price objective on shares of NewLink Genetics Corp. in a research report on Wednesday, May 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $23.29.

The stock’s market cap is $287.08 million. The company has a 50 day moving average price of $10.56 and a 200-day moving average price of $14.03.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its earnings results on Friday, July 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. Analysts anticipate that NewLink Genetics Corp. will post ($3.06) EPS for the current fiscal year.

A hedge fund recently raised its stake in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP boosted its position in NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned 0.17% of NewLink Genetics Corp. worth $1,765,000 as of its most recent filing with the SEC.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.